Skip to main content

Gene-editing startup incubated at Google goes public in $267M IPO

Verve Therapeutics, a cholesterol-targeting, gene-editing startup that's the first biotech to be incubated by the venture capital arm of Google, has hit the public market in a $267 million IPO — more than twice what it was originally hoping to raise.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.